Buchumschlag

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of anti-PD-1 and oncolytic measles vaccine in an imm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Veinalde, Rūta (VerfasserIn) , Pidelaserra Martí, Gemma (VerfasserIn) , Moulin, Coline (VerfasserIn) , Tan, Chin Leng (VerfasserIn) , Schäfer, Theresa E. (VerfasserIn) , Kang, Na (VerfasserIn) , Ball, Claudia R. (VerfasserIn) , Leichsenring, Jonas (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Kaderali, Lars (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Ungerechts, Guy (VerfasserIn) , Engeland, Christine Elisabeth (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022
In: Frontiers in immunology
Year: 2022, Jahrgang: 13, Pages: 1-16
ISSN:1664-3224
DOI:10.3389/fimmu.2022.1096162
Online-Zugang:Resolving-System, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2022.1096162
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1096162
Volltext
Verfasserangaben:Rūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Guy Ungerechts, Christine E. Engeland
Beschreibung
Zusammenfassung:IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of anti-PD-1 and oncolytic measles vaccine in an immunocompetent transplantable PDAC mouse model.MethodsWe characterized tumor-infiltrating T cells by immunohistochemistry, flow cytometry and T cell receptor sequencing. Further, we performed gene expression profiling of tumor samples at baseline, after treatment, and when tumors progressed. Moreover, we analyzed systemic anti-tumor and anti-viral immunity.ResultsCombination treatment significantly prolonged survival compared to monotherapies. Tumor-infiltrating immune cells were increased after virotherapy. Gene expression profiling revealed a unique, but transient signature of immune activation after combination treatment. However, systemic anti-tumor immunity was induced by virotherapy and remained detectable even when tumors progressed. Anti-PD-1 treatment did not impact anti-viral immunity.DiscussionOur results indicate that combined virotherapy and ICB induces anti-tumor immunity and reshapes the tumor immune environment. However, further refinement of this approach may be required to develop its full potential and achieve durable efficacy.
Beschreibung:Elektronische Reproduktion der Druck-Ausgabe 16. Januar 2023
Gesehen am 31.01.2023
Beschreibung:Online Resource
ISSN:1664-3224
DOI:10.3389/fimmu.2022.1096162

Ähnliche Einträge